All In Biotech

NDA 011792 · Mylan Speciality Lp

Soma

Carisoprodol · Oral · Muscle Relaxant

Novel

Last checked: Nov 20, 2026Latest source record: Apr 4, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1959

Apr 9, 1959

Approved uses

2

Original approval plus efficacy supplements

Registered trials

4

4 Phase 3, 0 recruiting

FAERS reports

19,021

13,059 serious, 4,017 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 29, 2025.

SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see Dosage and Administration (2) ]. SOMA is a muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. (1) Limitations of Use • Should only be used for acute treatment periods up to two or three weeks (1)

Mechanism: The mechanism of action of carisoprodol in relieving discomfort associated with acute painful musculoskeletal conditions has not been clearly identified. In animal studies, muscle relaxation induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 13, 2007 Supplement 41 · Efficacy LetterReviewLabel
  • Apr 9, 1959 Original approval · Type 1 - New Molecular Entity
3 products under this application
  • SOMA · CARISOPRODOL 250MG · CAPSULE, ORAL · Discontinued
  • SOMA · CARISOPRODOL 350MG · TABLET, ORAL · Prescription · TE AA
  • SOMA · CARISOPRODOL 250MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Carisoprodol" as an intervention, any sponsor and status, largest first.

All 4 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain1,624
  • completed suicide1,459
  • drug ineffective1,319
  • nausea1,294
  • headache1,102
  • anxiety992
  • depression990
  • fatigue989
  • toxicity to various agents917
  • insomnia829
  • vomiting819
  • drug dependence797

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004607
2005750
2006601
2007511
2008671
2009763
20101,289
20111,148
20121,433
20131,160
2014978
20151,366
20161,602
20171,086
20181,085
20191,059
20201,034
2021600
2022354
2023275
2024268
2025207
2026173

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Soma (Carisoprodol)

2024 spending

$1.5M

Beneficiaries

237

1,511 claims

Per beneficiary

$6,192

$10.08 per unit

View as table
YearSpending
2020$1,431,580
2021$1,470,409
2022$1,489,510
2023$1,547,299
2024$1,467,569

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 128 on PubMed

Sponsor: Mylan Speciality Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.